{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:38:04Z","timestamp":1784191084839,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.vaccine.2010.07.040","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T08:29:57Z","timestamp":1280478597000},"page":"6463-6469","source":"Crossref","is-referenced-by-count":29,"title":["Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO\u00ae (IC51), in 6 months of follow-up"],"prefix":"10.1016","volume":"28","author":[{"given":"Katrin","family":"Dubischar-Kastner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kaltenboeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.07.040_bib0005","article-title":"Japanese encephalitis","volume":"vol. III","author":"Burke","year":"1988"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0010","unstructured":"World Health Organisation. Health topics: encephalitis, Japanese. Available at http:\/\/www.wpro.who.int\/health_topics\/encephalitis_japanese\/ [accessed 27.11.09]."},{"key":"10.1016\/j.vaccine.2010.07.040_bib0015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0140-6736(91)92707-9","article-title":"Side-effects with Japanese encephalitis vaccine","volume":"337","author":"Anderson","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/clinids\/24.2.265","article-title":"Systemic reactions in U.S Marine Corps personnel who received Japanese encephalitis vaccine","volume":"24","author":"Berg","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0264-410X(97)00020-0","article-title":"Allergic mucocutaneous reactions to Japanese encephalitis vaccine","volume":"15","author":"Plesner","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0030","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0140-6736(91)91531-X","article-title":"Adverse reactions to Japanese encephalitis vaccine","volume":"338","author":"Ruff","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0035","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/0140-6736(90)91036-A","article-title":"Further experience with Japanese encephalitis vaccine","volume":"335","author":"Sanchez","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2005-836609","article-title":"Anaphylaxis after vaccination due to hypersensitivity to gelatin","volume":"218","author":"Kamin","year":"2006","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0045","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0264-410X(99)00480-6","article-title":"IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines","volume":"18","author":"Sakaguchi","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00431-001-0853-0","article-title":"Immediate allergic reactions after vaccination\u2014post marketing surveillance review","volume":"161","author":"Zent","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0264-410X(97)00152-7","article-title":"Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines","volume":"16","author":"Sakaguchi","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1034\/j.1398-9995.2001.056006536.x","article-title":"Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines","volume":"56","author":"Sakaguchi","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0065","first-page":"RR-1","article-title":"Inactivated Japanese Encephalitis Virus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"42","author":"US Department of Health and Human Services","year":"1993","journal-title":"Morb Mortal Wkly Rep (MMWR)"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0070","unstructured":"GACVS. Weekly Epidemiological Record No. 28, 2005, 80, 241-8. Available at: http:\/\/www.who.int\/wer\/2005\/wer8028.pdf [accessed 11.01.08]."},{"key":"10.1016\/j.vaccine.2010.07.040_bib0075","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0090","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1016\/j.vaccine.2009.05.034","article-title":"Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the Hepatitis A vaccine HAVRIX\u00ae1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study","volume":"27","author":"Kaltenb\u00f6ck","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0095","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0100","series-title":"Proceedings of the 11th conference of the International Society of Travel Medicine","article-title":"Long term immunity following vaccination with the inactivated Japanese encephalitis vaccine IC51 and immune response to a booster dose","author":"Dubischar-Kastner","year":"2009"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0105","series-title":"Statistics with confidence. Confidence intervals and statistical guidelines","first-page":"45","article-title":"Proportions and their differences","author":"Newcombe","year":"2007"},{"key":"10.1016\/j.vaccine.2010.07.040_bib0110","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenb\u00f6ck","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10010352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10010352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T03:55:51Z","timestamp":1544327751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10010352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":22,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0264410X10010352"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.07.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}